Daily Sepsis Research Analysis
Three impactful studies on sepsis span mechanistic immunology, diagnostic innovation, and global neonatal epidemiology. A JCI study identifies an activin A–Smad3 axis as a natural brake on innate inflammation in sepsis, a Clinical Chemistry pilot optimizes plasma metagenomics workflows for pathogen detection, and a large Ugandan cohort quantifies high mortality and antimicrobial resistance in neonatal sepsis, underscoring the need for context-specific empiric therapy.
Summary
Three impactful studies on sepsis span mechanistic immunology, diagnostic innovation, and global neonatal epidemiology. A JCI study identifies an activin A–Smad3 axis as a natural brake on innate inflammation in sepsis, a Clinical Chemistry pilot optimizes plasma metagenomics workflows for pathogen detection, and a large Ugandan cohort quantifies high mortality and antimicrobial resistance in neonatal sepsis, underscoring the need for context-specific empiric therapy.
Research Themes
- Innate immune regulation and anti-inflammatory braking mechanisms in sepsis
- Optimization of plasma metagenomic diagnostics for pathogen detection
- Antimicrobial resistance and outcomes in neonatal sepsis in low-resource settings
Selected Articles
1. Activin A activation of Smad3 mitigates innate inflammation in mouse models of psoriasis and sepsis.
The study identifies an activin A–driven, TGF-β–independent activation of Smad3 in macrophages as a natural brake on innate inflammation. By promoting mitochondrial ATP production and adenosine generation via CD73, this axis limits inflammatory outputs; macrophage-specific loss of activin A signaling worsened survival in murine sepsis.
Impact: Revealing a TGF-β–independent activin A–Smad3 anti-inflammatory pathway provides a mechanistically precise target to modulate dysregulated inflammation in sepsis. The in vivo survival signal in sepsis models strengthens translational potential.
Clinical Implications: Therapeutically enhancing activin A–Smad3 signaling (e.g., selective receptor agonism or Smad3 activation) may attenuate hyperinflammation in sepsis while preserving host defense. Patient selection and timing will be critical to avoid immunosuppression.
Key Findings
- Bacterial/viral ligands induce activin A via STAT5, which activates Smad3 (pSmad3C) in macrophages independently of TGF-β.
- Activin A–Smad3 signaling enhances mitochondrial ATP production and adenosine generation (via CD73), enforcing anti-inflammatory outputs.
- Macrophage-specific Acvr1b deletion increased mortality in murine sepsis due to uncontrolled inflammation.
Methodological Strengths
- Macrophage-specific genetic deletion (Acvr1bfl/fl-Lyz2cre) establishes causality in vivo.
- Mechanistic mapping from ligand-induced STAT5→activin A→pSmad3C with functional metabolic readouts (ATP, adenosine/CD73).
Limitations
- Findings are based on murine models and ex vivo human macrophages; clinical validation is lacking.
- Potential off-target or fibrosis-related effects of activin/TGF-β superfamily modulation require careful safety evaluation.
Future Directions: Test selective activin receptor agonists or Smad3 activators in clinically relevant sepsis models; define biomarkers for patient stratification and optimal timing; assess safety and dosing windows.
Phosphorylation of Smad3 is a critical mediator of TGF-β signaling, which plays an important role in regulating innate immune responses. However, whether Smad3 activation can be regulated in innate immune cells in TGF-β-independent contexts remains poorly understood. Here, we show that Smad3 is activated through the phosphorylation of its C-terminal residues (pSmad3C) in murine and human macrophages in response to bacterial and viral ligands, and this activation is mediated by activin A in a TGF-β-independent manner. Specifically, infectious ligands, such as LPS, induced secretion of activin A through the transcription factor STAT5 in macrophages, and activin A signaling in turn activated pSmad3C. This activin A/Smad3 axis controlled mitochondrial ATP production and ATP conversion into adenosine by CD73 in macrophages, enforcing an antiinflammatory mechanism. Consequently, mice with a deletion of activin A receptor 1b specifically in macrophages (Acvr1bfl/fl-Lyz2cre) succumbed more to sepsis as a result of uncontrolled inflammation and exhibited exacerbated skin disease in a mouse model of imiquimod-induced psoriasis. Thus, we have revealed a previously unrecognized natural brake to inflammation in macrophages that occurs through the activation of Smad3 in an activin A-dependent manner.
2. Etiology and Antimicrobial Resistance of Culture-Positive Infections in Ugandan Infants: A Cohort Study of 7000 Neonates and Infants.
In a prospective cohort of 7,323 Ugandan neonates and infants with suspected sepsis, 11% of blood cultures were positive, inpatient mortality was 12.1%, and case fatality for Gram-negative bloodstream infections reached 27.7%. High resistance to WHO first-line agents underscores the need to revise empiric regimens tailored to local resistance patterns.
Impact: This large LMIC cohort provides granular, contemporary data on neonatal sepsis etiology, resistance, and mortality—key inputs for policy, stewardship, and empiric therapy updates.
Clinical Implications: Hospitals in similar settings should reassess empiric neonatal sepsis regimens, strengthen microbiology capacity, and implement stewardship aligned with local AMR. Prioritize rapid diagnostics and early escalation for suspected Gram-negative BSI.
Key Findings
- Among 7,323 infants evaluated, 11% of blood cultures and 8.6% of nasopharyngeal swabs were positive.
- Inpatient mortality was 12.1% overall; Gram-negative bloodstream infections had 27.7% case fatality.
- Bacterial isolates showed high resistance to WHO-recommended first-line regimens (ampicillin/penicillin plus gentamicin).
Methodological Strengths
- Prospective design with standardized microbiology (BACTEC culture, MALDI-TOF identification, multiplex PCR).
- Large sample size across two hospitals with outcome follow-up to discharge or death.
Limitations
- Conducted at two sites in Kampala; generalizability to other regions may vary.
- Detailed organism-by-organism resistance profiles and lumbar puncture rates are limited in the abstract.
Future Directions: Implement and evaluate context-specific empiric regimens; expand surveillance to additional sites; integrate genomic epidemiology to track transmission and resistance mechanisms.
BACKGROUND: Epidemiological evidence about the etiology and antimicrobial resistance of neonatal infections remains limited in low-resource settings. We aimed to describe the etiology of neonatal infections in a prospective observational cohort study conducted at two hospital sites in Kampala, Uganda. METHODS: Babies admitted to either unit with risk factors or signs of sepsis, pneumonia, or meningitis had a blood culture, nasopharyngeal swab, and lumbar puncture (if indicated) collected. Basic demographics were collected, and babies were followed up until discharge or death to determine admission outcome. Blood cultures were processed using the BACTEC system and identification confirmed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Cerebrospinal fluid was processed using standard microbiological testing and swabs were processed using the multiplex real-time polymerase chain reaction assay. Antimicrobial susceptibilities of bacterial isolates to World Health Organization-recommended first-line antibiotics (ampicillin or benzylpenicillin and gentamicin) were assessed using e-tests. RESULTS: A total of 7323 infants with signs or risk factors for sepsis had blood cultures, 2563 had nasopharyngeal swabs, and 23 had lumbar punctures collected. Eleven percent of blood cultures and 8.6% of swabs were positive. Inpatient mortality was 12.1%, with 27.7% case fatality observed among infants with Gram-negative bloodstream infections. CONCLUSIONS: Our study demonstrates high levels of antimicrobial resistance and inpatient mortality from neonatal sepsis in the first months of life in Uganda. This underscores the pressing need for revised, context-specific antimicrobial treatment guidelines that account for the evolving landscape of antimicrobial resistance in neonatal sepsis.
3. Enrichment of Microbial DNA in Plasma to Improve Pathogen Detection in Sepsis: A Pilot Study.
In a prospective ICU cohort, combining ssDNA library prep with size selection boosted total microbial cfDNA by 204-fold but increased background, reducing genus-level pathogen sensitivity. Size-selected dsDNA achieved the highest sensitivity (82%), highlighting trade-offs that can guide optimized plasma metagenomic workflows.
Impact: Provides practical, head-to-head evidence to optimize plasma metagenomic library strategies for sepsis diagnostics, balancing yield and specificity.
Clinical Implications: Diagnostic labs can prioritize size-selected dsDNA for higher pathogen sensitivity while exploring ssDNA+size selection to reduce sequencing depth in select contexts; validation in larger sepsis cohorts is needed before clinical adoption.
Key Findings
- Size-selected ssDNA libraries increased total microbial cfDNA fraction by 204-fold versus conventional dsDNA (P < 0.0001).
- At the genus level, size-selected dsDNA achieved the highest pathogen detection sensitivity (82%), outperforming dsDNA (41%), ssDNA (71%), and size-selected ssDNA (35%).
- Trade-off observed: ssDNA + size selection enriches mcfDNA but increases background noise, limiting specificity.
Methodological Strengths
- Prospective sampling with serial daily blood draws and head-to-head comparison of four library strategies.
- Objective sensitivity analysis at genus level against culture-proven infections and background modeling.
Limitations
- Small number of infected patients (n=5) limits generalizability and precision estimates.
- Potential for contamination/background biases inherent to metagenomic workflows; limited to genus-level analysis.
Future Directions: Validate optimal library strategies in larger, multi-center sepsis cohorts; develop computational filters to suppress background; assess clinical impact on time-to-pathogen and antimicrobial stewardship.
BACKGROUND: Diagnosis of sepsis and timely identification of pathogens in critically ill patients remains challenging. Plasma metagenomic sequencing to detect microbial cell-free DNA (mDNA) has shown promise, but low abundance of mDNA in plasma limits sensitivity and necessitates high sequencing depth. mDNA is shorter and more fragmented than human cell-free DNA. Here, we evaluated whether combining single-stranded DNA (ssDNA) sequencing library preparation and size selection can enrich mDNA and improve pathogen detection. METHODS: We prospectively enrolled 48 trauma patients and collected daily blood samples during the first 10 days of intensive care unit (ICU) admission. For patients with culture-proven infections, we extracted plasma DNA, prepared double-stranded DNA (dsDNA) and ssDNA sequencing libraries, and applied size selection to exclude fragments >110 bp. Following sequencing, we performed taxonomic classification, and evaluated differences in mDNA fractions and in sensitivity for pathogen detection (compared to background noise). RESULTS: We analyzed 46 plasma samples from 5 patients who developed culture-proven infections, including 17 samples coincident with positive microbial cultures. Size-selected ssDNA libraries showed the total mDNA fraction 204-fold higher on average than conventional dsDNA libraries (P < 0.0001). However, for pathogen-specific DNA (at the genus level), the highest sensitivity was observed in size-selected dsDNA (82%), compared to dsDNA (41%), ssDNA (71%), and size-selected ssDNA (35%) library preparations. CONCLUSIONS: Our results demonstrate that combining ssDNA library preparation together with fragment size selection improves mDNA yield, potentially reducing sequencing requirements. However, at the genus level, this combination also increases background noise, which limits sensitivity for pathogen detection.